ストックスクリーナーアプリを入手
2.306
1.03%
-0.024
前日終値:
$2.33
開ける：
$2.29
24時間の取引高:
43,960
Relative Volume:
0.05
時価総額：
$244.76M
収益：
$45.44M
当期純損益:
$-35.43M
株価収益率:
-6.7824
EPS:
-0.34
ネットキャッシュフロー:
$-25.39M
1週間 パフォーマンス:
+7.26%
1か月 パフォーマンス:
+4.11%
6か月 パフォーマンス:
-50.52%
1年 パフォーマンス:
-47.83%
1日の値動き範囲:
$2.25
$2.31
1週間の範囲:
$2.02
$2.37
52週間の値動き範囲:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
MXCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.30 | 238.15M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
125.13 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.19 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.24 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.83 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.57 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-22 | 開始されました | Stephens | Overweight |
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
Published on: 2025-07-23 21:52:41 - Autocar Professional
What drives MaxCyte Inc. stock priceFree Technical Analysis Support - Autocar Professional
What analysts say about MaxCyte Inc. stockFree Real-Time Stock Data - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastHigh-yield capital appreciation - jammulinksnews.com
Is MaxCyte Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
How MaxCyte Inc. stock performs during market volatilityDaily Swing Candidates - Newser
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte shares trading for last time in London - Sharecast.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
MaxCyte shareholders approve equity plan expansion, AIM delisting By Investing.com - Investing.com UK
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing - Investing.com Australia
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
Maxcyte Inc (MXCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.17%
0.30%
大文字化:
|
ボリューム (24 時間):